COVID-19 AND MYASTHENIA GRAVIS RELATIONSHIP: A BRIEF LOOK
Keywords:
Myasthenia Gravis, Covid-19, SARS-CoV-2, PandemicAbstract
Introduction: Since infection by the Severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) was declared a pandemic by the World Health Organization (WHO), numerous efforts have been made in the fields of diagnosis and research into pathophysiological mechanisms and their complications. One of the fields that has shown the most complications by SARS-CoV-2 is neurology. So far, few studies have associated Myasthenia Gravis (MG) with Coronavirus infectious disease (COVID-19), but it is possible to establish this correlation, especially in patients undergoing long-term immunosuppression therapy. Objective: To briefly review case reports and observational studies of the growing literature regarding on the relantionship about COVID-19 and MG. Method: An integrative review was performed based on the literature available in the PubMed and Google Scholar databases, using the descriptors “myasthenia gravis” and “COVID-19” and “SARS-CoV-2”. This search included articles published up until 4th November 2020 in English or Spanish. After reading the articles available in their entirety, those related specifically to relationship between COVID-19 and SARS-CoV-2 with a specific aspect of MG were selected. It was initially found a total of 415 articles and 10 were finally selected. Results: The clinical patients management and a special attention to the respiratory condition and the monitoration of drug side effects have occur. Conclusion: Besides most of the cases go to recovery and good outcome, it is important to consider that preceding viral infections could trigger to myasthenic events.
References
COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). ArcGIS. Johns Hopkins University [Internet]. 2021 [accessed 2023 September 20]. https://COVID-19 Map - Johns Hopkins Coronavirus Resource Center (jhu.edu).
Legay C, Mei L. Moving forward with the neuromuscular junction. J Neurochem 2017; 142 Suppl 2:59-63.
Finsterer J, Papić L, Auer-Grumbach M. Motor neuron, nerve, and neuromuscular junction disease. Curr Opin Neurol 2011; 24(5):469-474.
Somani S, Agnihotri SP. Emerging Neurology of COVID-19. Neurohospitalist 2020; 10(4):281-286.
Hirano T, Murakami M. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity 2020; 19;52(5):731-733.
Guidon AC, Amato AA. COVID-19 and neuromuscular disorders. Neurology 2020; 94(22):959-969.
Huber M, Rogozinski S, Puppe W, Framme C, Höglinger G, Hufendiek K, Wegner F. Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient. Front Neurol 2020; 6;11:576153.
Moschella P, Roth P. Isolated COVID-19 Infection Precipitates Myasthenia Gravis Crisis: A Case Report. Clin Pract Cases Emerg Med 2020; 4(4):524-526.
Anand P, Slama MCC, Kaku M, Ong C, Cervantes-Arslanian AM, Zhou L, David WS, Guidon AC. COVID-19 in patients with myasthenia gravis. Muscle Nerve 2020; 62(2):254-258.
Restivo DA, Centonze D, Alesina A, Marchese-Ragona R. Myasthenia Gravis Associated With SARS-CoV-2 Infection. Ann Intern Med 2020; L20-0845.
Delly F, Syed MJ, Lisak RP, Zutshi D. Myasthenic crisis in COVID-19. J Neurol Sci 2020; 414:116888.
Camelo-Filho AE, Silva AMS, Estephan EP, Zambon AA, Mendonça RH, Souza PVS, Pinto WBVR, Oliveira ASB, Dangoni-Filho I, Pouza AFP, Valerio BCO, Zanoteli E. Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes. Front Neurol 2020; 11;11:1053.
Ramaswamy SB, Govindarajan R. COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome. J Neuromuscul Dis 2020; 7(3):361-364.
Sriwastava S, Tandon M, Kataria S, Daimee M, Sultan S. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review J Neurol 2020; 12:17.
Singh S, Govindarajan R. COVID-19 and generalized Myasthenia Gravis exacerbation: A case report. Clin Neurol Neurosurg 2020; 196:106045.
Mas Maresma L, Barrachina Esteve O, Navarro Vilasaró M, Moreno-Ariño M. Miastenia gravis asociada a la infección por SARS-CoV-2: una conjunción de factores. Rev Esp Geriatr Gerontol 2020; 55(6):360-361.
Lahiri D, Ardila A. COVID-19 Pandemic: A Neurological Perspective. Cureus 2020; 12(4):e7889.
Scoppetta C, Casciato S, Di Gennaro G. Speculative clues on Myasthenia gravis and COVID-19. Eur Ver Med Pharmacol Sci 2020; 24(15):7925-7926.
Uzawa A, Kanai T., Kawaguchi N., Oda F, Himuro K, Kuwabara S. Changes in inflammatory cytokine networks in myasthenia gravis. Sci Rep 2016; 6:25886.
Amiral J, Vissac AM, Seghatchian J. Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients? Transfus Apher Sci 2020; 59(3):102804.
Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, Song S, Ma Z, Mo P, Zhang Y. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect Dis 2020; 11;221(11):1762-1769.
Kanwar D, Imran M, Wasay M. Neurological involvement in COVID-19 infections; pathophysiology, presentation, and outcome. PJNS vol. 15: Iss.1, Article 2.
Steardo L, Steardo L Jr, Zorec R, Verkhratsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19. Acta Physiol (Oxf) 2020; 229(3):e13473.
Abdullahi A, Candan SA, Abba MA, Bello AH, Alshehri MA, Afamefuna Victor E, Umar NA, Kundakci B. Neurological and Musculoskeletal Features of COVID-19: A Systematic Review and Meta-Analysis. Front Neurol 2020; 26;11:687.
Solé G, Salort-Campana E, Pereon Y, Stojkovic T, Wahbi K, Cintas P, Adams D, Laforet P, Tiffreau V, Desguerre I, Pisella LI, Molon A, Attarian S; FILNEMUS COVID-19 study group. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neurol (Paris) 2020; Jun;176(6):507-515.
Calcagno N, Colombo E, Maranzano A, Pasquini J, Keller Sarmiento IJ, Trogu F, Silani V. Rising evidence for neurological involvement in COVID-19 pandemic. Neurol Sci 2020; 41(6):1339-1341.
Koc G, Odabasi Z, Tan E. Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis. J Clin Neuromuscul Dis 2020; 22(1):60-62.
Shukla S, Gultekin SH, Saporta M. Pearls & Oy-sters: Hydroxychloroquine-induced toxic myopathy mimics Pompe disease: Critical role of genetic test. Neurology 2019; b12;92(7):e742-e745.
Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Ver 2005;18;(2):CD002828.
Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014; 175(3):408-418.
